- Congruence's Revenir™ drug discovery engine identified diverse correctors of GCase designed to target the key biological dysfunction in Parkinson's disease patients with GBA1 mutations - -...

Mega Matrix Corp. ("MPU" or the "Company") (NYSE American: MPU), today announced that that its management attended APOS 2024 in Indonesia on September 25th. Hosted by Media Partners Asia in 2010,...

Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY® and TECVAYLI® monotherapies RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson &...

Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody

Katrina E. Bell-Jordan, Ph.D. will be inaugurated Oct. 4. Celebratory activities to be held Oct. 3-5. CHICAGO, Sept. 27, 2024 /PRNewswire/ -- Northeastern Illinois University (NEIU) will celebrate...